27 Jul 2007 - Corcept Therapeutics and Xceleron announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometry (AMS) technology.
In early 2003, Corcept initiated a discovery research program to identify and patent selective GR-II antagonists to develop a pipeline of products for proprietary use. Three distinct series of GR-II antagonists were identified. These compounds appear to be as potent as Corcept's lead product CORLUX(r) in blocking cortisol but, unlike CORLUX, they do not block the progesterone or other steroid receptors. Corcept will evaluate one of the compounds, one which develops particularly high plasma and brain concentrations in an animal model, in a human microdosing study using Xceleron's AMS technology.
Xceleron will carry out the work using ultra-sensitive AMS. This most sensitive measuring device enables human drug-metabolite profiling to be performed in the early stages of clinical development. This type of analysis allows drug developers to detect and measure ultra-low levels of both known and previously unknown metabolites producing data that isn't available using other analytical techniques. Early human profiling also helps identify the most suitable species for use in long term toxicology and pharmacology studies.
 |
www.bionity.com/news/e/66614 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/66614 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |